title: Measurement of mRNA of 11 biomarkers by RT-PCR to detect lymph node involvement in cervical cancer.
abstract: Lymph node metastases are a major prognostic factor in cervical carcinomas. The aim of this study was to characterize the expression of 11 markers in cervical tumors and negative lymph nodes and to determine which ones could be helpful for improving the specificity of molecular diagnosis of nodal involvement. Using TaqMan RT-PCR, we studied the expression of CK19, MUC1, HER1-HER4, VEGF, VEGF-C, uPA, MMP9, and PRAD1 in uterine cervical tumors and in histologically nonmetastatic lymph nodes of 8 patients diagnosed with locally advanced cervical cancer. We observed that CK19, MUC1, HER1-HER3, uPA, and VEGF had a significantly higher expression in cervical tumors than in the negative nodes, whereas VEGF-C expression level was higher in the negative nodes than in the tumors. PRAD1 harbored similar expression levels in the tumors and in the negative nodes. Interestingly, 1 of the 4 patients who presented a clinical recurrence, showed elevated HER1, HER2, uPA, and VEGF in the histologically negative nodes. Our results suggest that CK19, MUC1, HER1-3, uPA, and VEGF are biomarkers that have a higher expression in tumoral cervical tissues compared with the negative lymph nodes and could be useful to diagnose nodal involvement in uterine cervical carcinoma. Our results should encourage us in continue to investigate a greater number of patients, including patients with histologically involved nodes.
authors.affiliation: Laboratory of Human Molecular Oncology, Centre Oscar Lambret, Lille - France.
authors.forename: V
authors.initials: V
authors.lastname: Samouelian
authors.forename: F
authors.initials: F
authors.lastname: Revillion
authors.forename: N
authors.initials: N
authors.lastname: Alloy
authors.forename: V
authors.initials: V
authors.lastname: Lhotellier
authors.forename: E
authors.initials: E
authors.lastname: Leblanc
authors.forename: J P
authors.initials: JP
authors.lastname: Peyrat
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics*; D045744:Cell Line, Tumor; D066246:ErbB Receptors / Q000032:analysis / Q000235:genetics; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053539:Keratin-19 / Q000032:analysis / Q000235:genetics; D008207:Lymphatic Metastasis / Q000175:diagnosis*; D020780:Matrix Metalloproteinase 9 / Q000032:analysis / Q000235:genetics; D018396:Mucin-1 / Q000032:analysis / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis*; D066247:Receptor, ErbB-4; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods*; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis / Q000235:genetics; D002583:Uterine Cervical Neoplasms / Q000473:pathology*; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; D053539:Keratin-19; C060192:MUC1 protein, human; D018396:Mucin-1; D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A; C587689:ERBB4 protein, human; D066246:ErbB Receptors; D066247:Receptor, ErbB-4; D014568:Urokinase-Type Plasminogen Activator; D020780:Matrix Metalloproteinase 9